Piramal Pharma Ltd. (PPLPHARMA) fundamentals
Piramal Pharma Ltd. is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as PPLPHARMA (ISIN INE0DK501011). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Piramal Pharma Ltd. does
Piramal Pharma Limited is a global pharmaceutical company, which offers a portfolio of differentiated pharma products across a domestic and global distribution network. It operates approximately 17 development and manufacturing facilities across India, the United Kingdom/Europe, and North America. It has a commercial presence in over 100 countries. The Company operates under three business verticals: Piramal Pharma Solutions (PPS), an integrated Contract Development and Manufacturing Organization (CDMO); Piramal Critical Care (PCC), a Complex Hospital Generics (CHG) business; and Piramal Consumer Healthcare business, selling over-the-counter products. PPS caters to both drug substances - Active Pharmaceutical Ingredients (APIs), and drug products (formulations). PCC's complex hospital product portfolio comprises hospital-focused products in the areas of inhalation anesthesia, intrathecal therapy, injectable anesthesia and pain management, and other generic and specialty products.
Valuation and market data
| Last close | ₹211.35 |
|---|---|
| Market capitalisation | ₹28,003 crore |
| Enterprise value | ₹32,071 crore |
| P/E (TTM) | 0.00 |
| Price to book | 3.43 |
| Price to sales (TTM) | 1.80 |
| Book value per share | ₹61.61 |
| Dividend yield | 0.00% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Wed Oct 19 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹5,445 crore | ₹877 crore | ₹700 crore | 5.28 |
| Mar 2025 | ₹5,493 crore | ₹911 crore | ₹691 crore | 5.22 |
| Mar 2024 | ₹4,592 crore | ₹508 crore | ₹391 crore | 3.05 |
| Mar 2023 | ₹3,784 crore | ₹124 crore | ₹70 crore | 0.57 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 34.8% |
|---|---|
| Foreign institutions (FII) | 12.5% |
| Mutual funds | 13.2% |
| Other domestic institutions | 1.4% |
| Retail and others | 38.1% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.